Goiter in a Newborn Exposed to Lithium in Utero

  title={Goiter in a Newborn Exposed to Lithium in Utero},
  author={Florence Frassetto and Florence Tourneur Martel and Claude E Barjhoux and C{\'e}line Villier and Brigitte Le Bot and Françoise Vincent},
  journal={Annals of Pharmacotherapy},
  pages={1745 - 1748}
OBJECTIVE: To report a case of neonatal goiter and biological hypothyroidism in a newborn exposed to lithium in utero resulting from therapy given to the mother before and during her pregnancy. CASE SUMMARY: A male neonate, born at 37 weeks' gestation, presented with a goiter without other signs of hypothyroidism. His serum thyroid-stimulating hormone concentration was high and unbound tetrathyroxine concentration was low, indicating that chronic exposure to lithium was present. Oral thyroxine… 
Lithium during pregnancy and after delivery: a review
An up-to-date overview of the literature on lithium use during pregnancy and after delivery leading to clinical recommendations is provided.
Mild iodine deficiency in pregnancy in Europe and its consequences for cognitive and psychomotor development of children: a review.
The pharmacology of bipolar disorder during pregnancy and breastfeeding
Treating bipolar disorder in women during reproduction presents a significant challenge to the physician, and strategies are available that minimise the risk to the fetus and infant whilst still providing effective prophylaxis againstipolar disorder in the mother.
[The treatment of bipolar disorder during pregnancy and the postpartum period].
Each medication's effects on organ dysgenesis, neonatal toxicity, and neurobehavioral development, and their associated adverse events during pregnancy and the postpartum period are discussed, with a focus on the emerging literature.
Protocol of the PSYCHOTSH study: association between neonatal thyroid stimulating hormone concentration and intellectual, psychomotor and psychosocial development at 4–5 year of age: a retrospective cohort study
The results could lead to a reassessment of the recommended cut-off levels of 5 > mU/L used for monitoring iodine status of the population and the definition of new TSH cut-offs for determination of the severity of iodine status and for practical use in data reporting by neonatal screening centres.
The safety of medications for the treatment of bipolar disorder during pregnancy and the puerperium.
There have been an insufficient number of first trimester exposures to the newer anticonvulsant mood stabilisers, lamotrigine and oxcarbazepine, to determine whether there is a safety advantage in switching to these agents.
Lithium Use and Non-use for Pregnant and Postpartum Women with Bipolar Disorder
Data regarding lithium use during the peripartum and management recommendations for general psychiatric clinicians are reviewed and recent studies indicate that lithium use in pregnancy is associated with either no increased malformations risk or a small increase in risk for cardiac malformation.
Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy.
Lithium completely equilibrates across the placenta, and higher lithium concentrations at delivery are associated with more perinatal complications, and lithium concentrations can be reduced by brief suspension of therapy proximate to delivery.
Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers.
  • S. Gentile
  • Medicine, Psychology
    Bipolar disorders
  • 2006
This review compares information from the literature on the safety of lamotrigine, oxcarbazepine, risperidone, olanzapine, and quetiapine to the safety data on classic mood stabilizers during pregnancy and the postpartum period to suggest thatUntreated pregnant bipolar women are at an increased risk of poor obstetrical outcomes and relapse of affective symptoms.


A reevaluation of risk of in utero exposure to lithium.
More recent epidemiologic data indicate that the teratogenic risk of first-trimester lithium exposure is lower than previously suggested, and the clinical management of women with bipolar disorder who have childbearing potential should be modified with this revised risk estimate.
Occurrence of Goitre during Lithium Treatment
Of 330 patients given lithium for recurrent manic-depressive disorder 12 developed goitre after treatment periods of five months to two years. All the patients remained clinically euthyroid. Pressure
Congenital hypothyroidism: etiologies, diagnosis, and management.
  • S. Lafranchi
  • Medicine, Biology
    Thyroid : official journal of the American Thyroid Association
  • 1999
Thyroid scintigraphy, using 99mTc or 123I, is the most accurate diagnostic test to detect thyroid dysgenesis or one of the inborn errors of T4 synthesis, and may miss some cases of ectopic glands.
Thyroid disorders.
  • A. Kahn
  • Medicine, Biology
    The Journal of the Arkansas Medical Society
  • 1984
Thyroid dysfunctions are relatively common among women of reproductive age, and can affect fertility in various ways, resulting in anovulatory cycles, high prolactin levels, and sex hormone imbalances.
Thyroid disease, behavior, and psychopharmacology.
Endocrine disorders
Musculoskeletal problems in chronic renal failure are common, but investigations into their pathogenesis are complicated by the coexistence of renal endocrine failure and β2-microglobulin-related amyloid deposition in long-term dialysis patients.
The Place of Lithium in Biological Psychiatry
Lithium has revolutionized the treatment of affective disorders and its prophylactic effect in depression — both the depressed phase of manic-depressive illness, and recurrent depressive disorder — though less dramatic, has been found to be significant.